Kim Innes has replaced Actavis director Michael Cann as chair of the British Generic Manufacturers Association (BGMA).
Innes, a commercial director responsible for Teva UK’s generics business, will remain in the position for the next two years.
Cann will continue for a further year as vice-chair of the association, which is the generic industry’s trade body representing more than 90% of the UK supply market.
Innes has worked in the generics industry since 1991, said: ‘Over the coming two years, we will continue to focus on our three core objectives of increasing patient access to medicines, maintaining market efficiency and providing economic sustainability for the industry.’
